99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours:: results of 3 years' experience

被引:90
作者
Hubalewska-Dydejczyk, A. [1 ]
Froess-Baron, K.
Mikolajczak, R.
Maecke, H. R.
Huszno, B.
Pach, D.
Sowa-Staszczak, A.
Janota, B.
Szybinski, P.
Kulig, J.
机构
[1] Jagiellonian Univ, Coll Med, Dept Endocrinol, Nucl Med Unit, Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Gastrointestinal & Gen Surg Dept, Krakow, Poland
[3] Radioisotope Ctr POLATOM, Otwock, Poland
[4] Univ Hosp, Radiol Chem Unit, Basel, Switzerland
关键词
carcinoid tumour; somatostatin analogues; somatostatin receptor scintigraphy; Tc-99m-EDDA/HYNIC-octreotate; In-111-Octreoscan;
D O I
10.1007/s00259-006-0113-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: At all stages of the disease, serious difficulties are encountered in the imaging diagnosis of carcinoids. Somatostatin receptor scintigraphy (SRS) holds great promise for detecting primary tumours and metastases. Tc-99m-EDDA/HYNIC-octreotate should significantly improve the diagnosis of carcinoids in comparison with In-111-Octreoscan owing to the better affinity for SSR2 and the higher count rate. The aim of this study was to assess the diagnostic efficiency of Tc-99m-EDDA/HYNIC-octreotate scintigraphy in the detection and staging of carcinoid tumours. Methods: The study population comprised 75 patients (age 48.5 +/- 15.5 years): 46 with histological confirmation of carcinoid and 29 with suspected disease. Tc-99m-EDDA/HYNIC-octreotate (740 MBq) SRS and CT were performed in all patients. Fifteen patients were examined with In-111-Octreoscan. Results: High-quality Tc-99m-EDDA/HYNIC-octreotate images were obtained in all cases, with maximum tumour tracer accumulation 4 h p.i. The mean target/non-target ratios for whole body (WB) and SPECT scans were, respectively, as follows: primary lesions: 4.5 and 10.2; metastases: liver, 3.1 and 12.3; abdominal focal lesions, 2.7 and 5.8; lung, 2.7 and 8.3; mediastinum, 3.4 and 7.6; bones, 6.8 and 19.0. Tc-99m-EDDA/HYNIC-octreotate WB scans revealed more metastases than In-111-Octreoscan, with better individual separation. Tc-99m-EDDA/HYNIC-octreotate SRS revealed new metastatic lesions in seven patients with confirmed carcinoid, and in four with dissemination the primary focus was found. Five patients qualified for radioguided surgery and 11 were referred to Y-90-DOTA-TATE therapy. The sensitivity of SRS in comparison with CT was higher for primary lesions and liver and abdominal lymph node metastases. In the subgroup of patients with suspected neuroendocrine tumours, two duodenal carcinoids, one thymic carcinoid and one ileal carcinoid were found. Tc-Conclusion: 99m-EDDA/HYNIC-octreotate, with high imaging quality, is an excellent alternative to In-111-Octreoscan for staging of carcinoids, and it seems to be the method of choice for detection of the primary focus in patients with metastases from an unknown primary tumour.
引用
收藏
页码:1123 / 1133
页数:11
相关论文
共 35 条
[21]   Tc-99m labeling of highly potent small peptides [J].
Liu, S ;
Edwards, DS ;
Barrett, JA .
BIOCONJUGATE CHEMISTRY, 1997, 8 (05) :621-636
[22]   Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours [J].
Öberg, K ;
Eriksson, B .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 19 (02) :265-276
[23]   Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide [J].
Paganelli, G ;
Zoboli, S ;
Cremonesi, M ;
Bodei, L ;
Ferrari, M ;
Grana, C ;
Bartolomei, M ;
Orsi, F ;
De Cicco, C ;
Mäacke, HR ;
Chinol, M ;
de Braud, F .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (04) :426-434
[24]   Somatostatin and its receptor family [J].
Patel, YC .
FRONTIERS IN NEUROENDOCRINOLOGY, 1999, 20 (03) :157-198
[25]   Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics:: a preliminary communication [J].
Plachcinska, A ;
Mikolajczak, R ;
Maecke, HR ;
Mlodkowska, E ;
Kunert-Radek, J ;
Michalski, A ;
Rzeszutek, K ;
Kozak, J ;
Kusmierek, J .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (10) :1402-1406
[26]   Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours [J].
Ramage, JK ;
Davies, AHG ;
Ardill, J ;
Bax, N ;
Caplin, M ;
Grossman, A ;
Hawkins, R ;
McNicol, AM ;
Reed, N ;
Sutton, R ;
Thakker, R ;
Aylwin, S ;
Breen, D ;
Britton, K ;
Buchanan, K ;
Corrie, P ;
Gillams, A ;
Lewington, V ;
McCance, D ;
Meeran, K ;
Watkinson, A .
GUT, 2005, 54 :iv1-iv16
[27]   Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use [J].
Reubi, JC ;
Schär, JC ;
Waser, B ;
Wenger, S ;
Heppeler, A ;
Schmitt, JS ;
Mäcke, HR .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (03) :273-282
[28]  
Schillaci O, 2003, J NUCL MED, V44, P359
[29]   Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan):: a comparative study with CT and MR imaging [J].
Shi, W ;
Johnston, CF ;
Buchanan, KD ;
Ferguson, WR ;
Laird, ID ;
Crothers, JG ;
McIlrath, EM .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (04) :295-301
[30]   Early-stage carcinoids of the gastrointestinal tract - An analysis of 1914 reported cases [J].
Soga, J .
CANCER, 2005, 103 (08) :1587-1595